NL-OMON36430已完成不适用
The effect of GLP-1 receptor activation on central reward and satiety circuits in response to food stimuli in obesity and diabetes. - Braini-Ex
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •For all 3 study groups:
- •1. age 18*70 years.
- •2. Men and women. For women, only postmenopausal women (as ascertained by serum FSH) will be included in order to avoid variations related to the menstrual cycle.
- •3.To promote comparability and to overcome the interference of lateralization, only right-handed persons will be included.;For the healthy lean subjects, inclusion criteria will be:
- •1.body-mass index (BMI) of <25 kg/m2
- •2.stable bodyweight (<5% reported change during the previous 3 months)
- •3.Normal fasting and 2-h postload glucose as ascertained during a 75-g oral glucose tolerance test (OGTT);For the normoglycemic obese individuals, inclusion criteria will be:
- •1.body-mass index (BMI) *30 kg/m2
- •2.stable bodyweight (<5% reported change during the previous 3 months)
- •3.Normal fasting and 2-h postload glucose as ascertained during a 75-g oral glucose tolerance test (OGTT) ;For the obese T2DM individuals, inclusion criteria will be:
- •1.Diagnosed with T2DM (20) > 3 months prior to screening
- •2. BMI *30 kg/m2
- •3.HbA1c 6.5*8.5% (48-69 mmol/mol)
- •4.Treatment with metformin at a stable dose for at least 3 months.
排除标准
- •In the obese T2DM patients, no blood glucose- and weight lowering agents will be allowed within 3 months before screening except for metformin. The normoglycemic lean and obese individuals will not be allowed to take blood glucose-lowering agents at any time before and during the study.
- •For all individuals, exclusion criteria will be:
- •1.congestive heart failure (NYHA II-IV)
- •2.chronic renal failure (glomerular filtration rate < 60 mL/min/1.73m2 per Modification of Diet in Renal Disease (MDRD)) or serious liver impairment
- •3.a history of gastrointestinal disorders, including gastroparesis, pancreatitis and cholelithiasis
- •4.neurological illness
- •5.malignancy
- •6.pregnancy or breast feeding
- •7.implantable devices
- •8.substance abuse
- •9.addiction
- •10.contra-indication for MRI, such as claustrophobia or pacemaker
- •11.any psychiatric illness, including eating disorders and depression
- •12.hypersensitivity to the active substance or to any of the excipients
- •13.chronic use of glucocorticoids or centrally acting drugs within 2 weeks immediately prior to screening
- •14.use of cytostatic or immuno-modulatory agents
- •15.participation in other studies
- •16.individuals who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- •17.individuals who are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
- •18.individuals who have previously completed or withdrawn from this study or any other study investigating GLP-1 receptor agonist or dipeptidyl peptidase (DPP)-4 within 6 months
- •19.individuals, who in the opinion of the investigator, are unsuitable in any other way to participate in this study
- •20.individuals who are employed by Amylin Pharmaceutical Inc. or Eli Lilly & company (that is, employees, temporary contract workers, or designees responsible for conducting the study). Immediate family of Amylin or Lilly employees may participate in sponsored clinical trials, but are not permitted to participate at an Amylin or Lilly facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
- •21.poor commandment of the Dutch language or any (mental) disorder that precludes full understanding the purpose, instruction and hence participation in the study.
研究者
相似试验
已完成
不适用
The influence of GLP-1 receptor agonist on the heart rate using holter electrocardiography and power spectrum analysis on heart rate variabilityType 2 diabetesJPRN-UMIN000017770Dokkyomedical university nikko medical center50
已完成
不适用
Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the BrainDiabetes MellitusNCT02745470Seoul National University Hospital30
进行中（未招募）
1 期
Effects of Saxenda (R) on respiratory function in obese patients with chronic obstructive lung diseaseChronic obstructive pulmonary disease in obese subjectsMedDRA version: 20.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003551-32-DKHospital of South West Jutland40
进行中（未招募）
1 期
Does stimulation of the receptor for Glucagon-like Peptide 1 (GLP-1) reduce alcohol intake in patients with alcohol dependence?Alcohol dependenceEUCTR2016-003343-11-DKPsychiatric Centre Copenhagen169
已完成
不适用
The effect of the cognitive function of GLP-1 receptor agonist in Type 2 diabtes patients with mild cognitive dysfunction. - prospective,randomized,active-controlled studyType 2 diabetes with mild cognitive disfunctionJPRN-UMIN000017592Tokyo medical university, Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Department of Gerontology40